• IP addresses are NOT logged in this forum so there's no point asking. Please note that this forum is full of homophobes, racists, lunatics, schizophrenics & absolute nut jobs with a smattering of geniuses, Chinese chauvinists, Moderate Muslims and last but not least a couple of "know-it-alls" constantly sprouting their dubious wisdom. If you believe that content generated by unsavory characters might cause you offense PLEASE LEAVE NOW! Sammyboy Admin and Staff are not responsible for your hurt feelings should you choose to read any of the content here.

    The OTHER forum is HERE so please stop asking.

China, US team up to develop cure for Mers virus as South Korea reports 16th death

EndoftheWorld

Alfrescian
Loyal
Joined
Jul 20, 2012
Messages
138
Points
0

China, US team up to develop cure for Mers virus as South Korea reports 16th death

An antibiotic is in the works and has already proven effective on animals, mainland official says

PUBLISHED : Monday, 15 June, 2015, 11:55pm
UPDATED : Tuesday, 16 June, 2015, 8:28am

Lawrence Chung and Agence France-Presse

sk-mers-ap-net.jpg


A couple wears masks as a precaution against the Middle East respiratory syndrome virus as they walk in Myeongdong, one of Seoul's main shopping districts, on Monday. Photo: AP

Fudan University and the United States’ National Institute of Health are jointly developing a Mers antibiotic, as South Korea on Monday reported its 16th death in the outbreak that has badly affected its tourism industry.

More than 100,000 travellers have stayed away from South Korea because of the deadly Middle East respiratory syndrome. The country was expected to lose US$2.3 billion in tourism if the situation did not improve, a South Korean official said.

Guangdong’s Mers response team leader Zhong Nanshan said the antibiotic that Fudan University in Shanghai and the US agency were developing had been proven effective on animals.

Fudan academic Jiang Shibo said his team had designed a Mers-resistant polypeptide HR2P that inhibited the deadly Mers virus from infecting cells.

Jiang was quoted by China Science Daily as saying his team was improving the antibody to produce a soluble antiviral drug that was more stable and active.

The US requires any new drug to undergo four phases – laboratory tests, animal testing, trials on humans and approval from the US Food and Drug Administration – before it can be marketed.

Based on the trial results so far, the polypeptide could theoretically be used in the form of a nasal spray by high-risk groups such as medical staff as a preventative measure, Jiang said.

The news of the Mers antibiotic came as South Korea declared five new Mers cases – bringing its total to 150. The virus has claimed 16 lives since it broke out in the country less than a month ago. A 58-year-old man with diabetes was the latest death.

South Korea’s tourism vice-minister Kim Chong said more than 100,000 foreigners had cancelled trips to the country since the month began. Foreign currency earnings were expected to drop by US$2.3 billion if tourist numbers were halved, he said.

“Our tourism industry is faced with a very dire situation,” Kim said, pledging US$64 million of aid for tourism-related businesses. An average of 1.18 million people each month visited South Korea last year.

South Korea’s Mers outbreak started on May 20 when a 68-year-old man was diagnosed after a trip to Saudi Arabia.

One patient became the mainland’s first confirmed case after the 44-year-old man ignored doctors’ advice and flew from Seoul to Hong Kong before travelling by coach to Huizhou in Guangdong.

The man’s condition was now stable and he could soon be discharged from hospital, Zhong told China Business News.

“The patient has shown no fever symptoms for six consecutive days and has developed antibodies against the virus since June 9,” he said.

On Friday, samples from the man’s mucus, blood and urine all tested negative for Mers, and only a small amount of the virus was found in his excrement, Zhong said. He added that once the patient made a full recovery, he would not get infected again or transmit the virus to others.

“The patient has already developed his own antibodies that would stop him from becoming infected again,” he said.

Although Mers had been around since 2012, it drew more international attention only this year after the virus was brought from the Middle East to other countries, Zhong said.

“We have made certain progress in developing the antibody for Mers, but the development has not yet come to the clinical phase, making it impossible for use in patients because of safety concerns,” he said.


 
Back
Top